Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Age
18–45
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Provision of informed consent prior to any study specific procedures
Male or female subjects aged 18 to 45 years (inclusive)
Minimum weight of 50 kg and body mass index (BMI) between 18 and 30 kg/m2 (inclusive)
Female subjects must have a negative pregnancy test at screening and on Day -1,must not be lactating, and must be of non-childbearing potential
You may not be if
History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs (except for cholecystectomy)
Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of the investigational product
Subjects who smoke more than 5 cigarettes or the equivalent in tobacco per day
Absolute neutrophil count of \<2500/mm3 or 2.5 x 109/L
Previous treatment with fostamatinib or digoxin in the present study
Clareo Health | Effects of Administration of Fostamatinib on Blood Concentrations of Digoxin in Healthy Subjects
